Skip to main content
Figure 2 | Journal of Clinical Movement Disorders

Figure 2

From: Effect of prior exposure to dopamine agonists on treatment with gabapentin enacarbil in adults with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 randomized trials

Figure 2

IRLS Rating Scale total score changes from baseline by visit in DA-naive (A) and DA-exposed (B) patients. MMRM analysis. Change from baseline reported as the LS mean change from baseline. Within the placebo group, there were no statistically significant differences in change in IRLS Rating Scale total score from baseline between the DA-naive vs DA-exposed patients in any treatment arm at any of the visits, except at week 1. Within the GEn 600-mg and GEn 1200-mg groups, there were no statistically significant differences in change in IRLS Rating Scale total score from baseline between the DA-naive vs DA-exposed patients in any treatment arm at any of the visits. DA, dopamine agonist; GEn, gabapentin enacarbil; IRLS, International Restless Legs Scale; LS, least squares; MMRM, mixed-effect model for repeated measures; W, week.

Back to article page

Journal of Clinical Movement Disorders

ISSN: 2054-7072

Contact us